Clinical trial
A Phase I/II, Multicenter, Randomized, Double-blind, Placebo Within-patient Controlled, First-in-human (FIH) Proof of Concept (PoC) Study to Evaluate the Safety and Efficacy of Topically Applied SXR1096 Cream in Patients With Netherton Syndrome (NS)
NCT05211830 is registered in ClinicalTrials.gov with Sixera Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II, Multicenter, Randomized, Double-blind, Placebo Within-patient Controlled, First-in-human (FIH) Proof of Concept (PoC) Study to Evaluate the Safety and Efficacy of Topically Applied SXR1096 Cream in Patients With Netherton Syndrome (NS)
- Lead sponsor
- Sixera Pharma
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- December 7, 2021
- Completion date
- August 20, 2025
- Enrollment
- 9 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.